PBM
OVID icon

Propel Bio Management’s Ovid Therapeutics OVID Stock Holding History

Propel Bio Management’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3M Buy
1,115,538
+194,081
+21% +$501K 1.57% 21
2026
Q1 		$2.04M Buy
+921,457
New +$1.65M 1.28% 26

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Propel Bio Management's OVID Position: Q2 2026 in Review

Propel Bio Management increased its Ovid Therapeutics (OVID) stake by 21% in Q2 2026, buying an estimated $501K and bringing the position to 1,115,538 shares worth $3M. The position accounts for 1.57% of the portfolio, ranked #21.

Propel Bio Management first reported a position in OVID in Q1 2026 and has held it in 2 quarters since. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Propel Bio Management held 1,115,538 shares of Ovid Therapeutics worth $3M as of Q2 2026.
  • Propel Bio Management bought 194,081 Ovid Therapeutics shares in Q2 2026, an estimated $501K.
  • Ovid Therapeutics made up 1.57% of Propel Bio Management's portfolio in Q2 2026, its #21 holding.
  • Propel Bio Management first reported a position in Ovid Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.